Aarti Pharmalabs Ltd

Aarti Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aarti Pharmalabs Ltd

₹ 677 2.74%
16 Sep 3:45 p.m.
aartipharmalabs.com BSE: 543748 NSE: AARTIPHARM
About

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

Key Points

Business Overview:[1]
Aarti Pharmalabs Limited (APL) formerly known as Aarti Organics was established in 1984 as a WOS of Aarti Industries Limited. Got demerged in Oct,22 into a separately listed entity.
Co. is an internationally recognized manufacturer of generic API & Intermediates, Xanthine derivatives and offers CDMO/CMO services. Company has 6 manufacturing plants and 3 R&D centres.

Website BSE NSE
  • Market Cap ₹ 6,134 Cr.
  • Current Price ₹ 677
  • High / Low ₹ 722 / 371
  • Stock P/E 27.3
  • Book Value ₹ 194
  • Dividend Yield 0.46 %
  • ROCE 16.6 %
  • ROE 13.1 %
  • Face Value ₹ 5.00
Edit ratios

Pros

Cons

  • Company has a low return on equity of 13.9% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024
460 457 531 472 485 458 440 449 506 555
385 371 441 385 405 373 352 353 388 459
Operating Profit 76 86 90 86 80 85 88 96 118 96
OPM % 16% 19% 17% 18% 16% 19% 20% 21% 23% 17%
3 0 1 0 1 0 1 1 2 2
Interest 5 4 6 5 6 4 4 4 5 5
Depreciation 14 14 17 16 16 17 18 19 19 20
Profit before tax 59 68 69 65 59 64 67 74 96 74
Tax % 18% 24% 26% 27% 27% 26% 23% 29% 32% 25%
49 52 51 48 43 47 52 53 65 55
EPS in Rs 5.26 4.73 5.20 5.72 5.82 7.20 6.12
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
0 1,200 1,945 1,853 1,950
0 993 1,603 1,467 1,552
Operating Profit 0 207 342 386 398
OPM % 17% 18% 21% 20%
0 3 2 5 7
Interest 0 12 21 17 18
Depreciation 0 42 63 73 76
Profit before tax 0 155 261 300 310
Tax % 21% 26% 28%
0 122 193 217 225
EPS in Rs 21.35 23.93 24.86
Dividend Payout % 0% 9% 13%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 0%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 19%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 40%
Return on Equity
10 Years: %
5 Years: %
3 Years: 14%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 0 0 45 45
Reserves -0 1,386 1,513 1,712
0 341 215 285
0 312 470 540
Total Liabilities 0 2,040 2,244 2,582
0 782 926 1,033
CWIP 0 187 102 137
Investments 0 32 87 107
0 1,038 1,130 1,305
Total Assets 0 2,040 2,244 2,582

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024
0 -44 250 216
0 -139 -158 -215
0 260 -163 10
Net Cash Flow 0 78 -71 12

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 115 84 102
Inventory Days 272 188 230
Days Payable 123 106 135
Cash Conversion Cycle 264 166 197
Working Capital Days 214 134 163
ROCE % 19% 16% 17%

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
45.98% 45.98% 46.30% 46.46% 46.46% 46.46%
7.69% 7.43% 8.45% 8.17% 8.33% 7.07%
13.68% 10.65% 10.51% 9.91% 9.97% 11.47%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
32.64% 35.92% 34.73% 35.45% 35.24% 35.00%
No. of Shareholders 2,76,6642,58,2392,26,2862,15,7962,04,1221,89,012

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls